Safety Board OKs Continuation of Phase 2b Trial of Lanifibranor as a Systemic Sclerosis Treatment
News
A data safety monitoring board (DSMB) has recommended that Inventiva continue its Phase 2b clinical trial assessing lanifibranor (previously known as IVA337) for the treatment of diffuse cutaneous scleroderma, after reviewing data gathered in ... Read more